Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 5/20 | 0.47 |
| ▸ | NPY1R | P25929 | 4/20 | 0.47 |
| ▸ | NPY2R | P49146 | 4/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063663 | 0.93 | NTSR2 (0.54) | F2ACENTSR2NTSR1NPY4R | |
| SCHEMBL29974534 | 0.88 | NTSR2 (0.54) | F2NTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL29974987 | 0.88 | NTSR2 (0.54) | F2NTSR2NTSR1NPY4RNPY1R | |
| SCHEMBL30405655 | 0.88 | ACE (0.50) | F2ACENTSR2NTSR1NPY4R | |
| SCHEMBL30682522 | 0.87 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30450371 | 0.87 | F2 (0.57) | F2PLG | |
| SCHEMBL29974829 | 0.85 | F2 (0.52) | F2NTSR2NTSR1 | |
| SCHEMBL29429777 | 0.85 | GHSR (0.56) | F2PLG | |
| SCHEMBL11044131 | 0.85 | OPRK1 (0.53) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL11043731 | 0.85 | OPRK1 (0.53) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | F2 3097/4885ACE 3820/4885NTSR2 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.